Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.

Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):909-15. doi: 10.1016/j.ijrobp.2011.09.008. Epub 2011 Dec 13.

PMID:
22172900
2.

Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer.

Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P.

Radiother Oncol. 2009 Aug;92(2):226-30. doi: 10.1016/j.radonc.2009.04.010. Epub 2009 May 10.

PMID:
19435643
3.

High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.

Chang JS, Wang ML, Koom WS, Yoon HI, Chung Y, Song SY, Seong J.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1448-54. doi: 10.1016/j.ijrobp.2011.10.050. Epub 2012 Jan 27.

PMID:
22285669
4.

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.

Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE.

Radiat Oncol. 2012 Mar 2;7:28. doi: 10.1186/1748-717X-7-28.

5.

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.

Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS.

Cancer. 2012 Jun 15;118(12):3026-35. doi: 10.1002/cncr.26633. Epub 2011 Oct 21.

6.

Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.

Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e749-57. doi: 10.1016/j.ijrobp.2010.10.034. Epub 2011 Mar 21.

PMID:
21420250
7.

A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.

Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):163-9. doi: 10.1016/j.ijrobp.2012.03.059. Epub 2012 Jun 5.

PMID:
22677367
8.

Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.

Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):921-6. doi: 10.1016/j.ijrobp.2011.08.022. Epub 2011 Dec 28.

PMID:
22208966
9.

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.

Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J.

BMC Cancer. 2012 Dec 20;12:609. doi: 10.1186/1471-2407-12-609.

10.

Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.

Ogawa K, Ito Y, Hirokawa N, Shibuya K, Kokubo M, Ogo E, Shibuya H, Saito T, Onishi H, Karasawa K, Nemoto K, Nishimura Y; Japanese Radiation Oncology Study Group Working Subgroup of Gastrointestinal Cancers.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):559-65. doi: 10.1016/j.ijrobp.2011.07.013. Epub 2011 Oct 20.

PMID:
22019243
11.

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.

Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB.

Cancer Chemother Pharmacol. 2012 Sep;70(3):381-9. doi: 10.1007/s00280-012-1918-7. Epub 2012 Jul 18.

PMID:
22806305
12.

Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.

Huang WK, Kuo YC, Tsang NM, Hsu HC, Shen WC, Chou WC, Yang TS, Chen JS.

Anticancer Res. 2014 Nov;34(11):6755-61.

PMID:
25368287
13.

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).

Vestermark LW, Jacobsen A, Qvortrup C, Hansen F, Bisgaard C, Baatrup G, Rasmussen P, Pfeiffer P.

Acta Oncol. 2008;47(3):428-33. doi: 10.1080/02841860701798866.

PMID:
18348002
14.

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.

Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.

Cancer. 2013 Jan 15;119(2):277-84. doi: 10.1002/cncr.27736. Epub 2012 Jul 6.

15.

Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):119-25. doi: 10.1016/j.ijrobp.2010.01.027. Epub 2010 Jun 3.

PMID:
20605363
16.

Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.

Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):369-75. doi: 10.1016/j.ijrobp.2011.12.026. Epub 2012 Feb 28.

PMID:
22381898
17.

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.

Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e337-43. doi: 10.1016/j.ijrobp.2011.12.068. Epub 2012 Mar 11.

PMID:
22414286
18.

Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.

Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O.

Radiother Oncol. 2015 Jan;114(1):122-7. doi: 10.1016/j.radonc.2015.01.004. Epub 2015 Jan 19.

PMID:
25614389
19.

Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.

Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M.

Ann Surg. 2010 Mar;251(3):461-9. doi: 10.1097/SLA.0b013e3181cc90a3.

PMID:
20134315
20.

Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.

Fujino Y, Ueda T, Kamigaki T, Takase S, Ajiki T, Kamoda Y, Matsumoto I, Yasuda T, Kuroda Y.

Pancreas. 2007 Apr;34(3):335-9.

PMID:
17414056

Supplemental Content

Support Center